Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22

Benzinga · 3d ago
Leerink Partners analyst Thomas Smith maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $28 to $22.